CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

22 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

20 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

24 янв 2024 08:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 ноя 2023 08:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 окт 2023 15:01:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 сен 2023 06:35:51 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 сен 2023 06:30:58 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 авг 2023 15:05:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

02 авг 2023 15:01:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 июл 2023 07:30:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 июн 2023 08:25:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 июн 2023 08:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 июн 2023 08:15:00 Источник Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 май 2023 15:01:01 Источник Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire